[{"address1": "#21-1344 Summer Street", "city": "Halifax", "state": "NS", "zip": "B3H 0A8", "country": "Canada", "phone": "902-442-4655", "website": "https://www.appilitherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Donald D. Cilla Jr., M.B.A., Pharmd", "title": "CEO, President & Director", "fiscalYear": 2023, "totalPay": 418617, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth G. Howling", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 384991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary S. Nabors Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0222, "open": 0.023, "dayLow": 0.023, "dayHigh": 0.023, "regularMarketPreviousClose": 0.0222, "regularMarketOpen": 0.023, "regularMarketDayLow": 0.023, "regularMarketDayHigh": 0.023, "beta": 1.115, "forwardPE": -0.46, "volume": 998, "regularMarketVolume": 998, "averageVolume": 119700, "averageVolume10days": 344440, "averageDailyVolume10Day": 344440, "marketCap": 3239228, "fiftyTwoWeekLow": 0.016, "fiftyTwoWeekHigh": 0.076, "priceToSalesTrailing12Months": 2.8169968, "fiftyDayAverage": 0.02238, "twoHundredDayAverage": 0.02949, "currency": "USD", "enterpriseValue": 10101254, "floatShares": 106833026, "sharesOutstanding": 121266000, "heldPercentInsiders": 0.00062, "heldPercentInstitutions": 0.11841, "impliedSharesOutstanding": 140836000, "bookValue": -0.081, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -5338095, "trailingEps": -0.03, "forwardEps": -0.05, "enterpriseToRevenue": 8.785, "enterpriseToEbitda": -1.286, "52WeekChange": -0.120000005, "SandP52WeekChange": 0.27220368, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "APLIF", "underlyingSymbol": "APLIF", "shortName": "APPILI THERAPEUTICS INC", "longName": "Appili Therapeutics Inc.", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "df37bddd-c23d-386d-a253-a2f33cea7c20", "messageBoardId": "finmb_330222442", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.023, "targetHighPrice": 0.15, "targetLowPrice": 0.15, "targetMeanPrice": 0.15, "targetMedianPrice": 0.15, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 602884, "totalCashPerShare": 0.005, "ebitda": -7853629, "totalDebt": 8012030, "quickRatio": 0.405, "currentRatio": 0.46, "totalRevenue": 1149887, "revenuePerShare": 0.009, "returnOnAssets": -2.15782, "freeCashflow": -4251751, "operatingCashflow": -3116976, "grossMargins": 1.0, "operatingMargins": -4.01262, "financialCurrency": "CAD", "trailingPegRatio": null}]